October 13, 2018

CDMO: Avid Bioservices, Inc. Stock

by Wilton Risenhoover

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M)	783.46
Enterprise Value ($M)	903.94
Book Value ($M)	58.64
Book Value / Share	0.92
Price / Book	13.36
NCAV ($M)	-172.39
NCAV / Share	-2.70
Price / NCAV	-4.54

Profitability (mra)
Return on Invested Capital (ROIC)	-0.54
Return on Assets (ROA)	-0.32
Return on Equity (ROE)	-0.78

Liquidity (mrq)
Quick Ratio	1.05
Current Ratio	1.46

Balance Sheet (mrq) ($M)
Current Assets	103.62
Assets	334.64
Liabilities	276.01
Debt	n/a
Equity	n/a

Income Statement (mra) ($M)
Revenue	0.00
Operating Income	0.00
Net Income	0.00
Earnings Per Share Basic And Diluted	n/a
Earnings Per Share Diluted	n/a
Earnings Per Share Basic	n/a

Cash Flow Statement (mra) ($M)
Cash From Operations	0.00
Cash from Investing	0.00
Cash from Financing	0.00
(click for more detail)

File Date	Form	Activist 13D/G Investors	Ownership (%)	Change (%)
9 days ago	13G/A	Point72 Asset Management, L.P.	8.30	63.75
11-12	13G/A	Integrated Core Strategies (us) Llc	1.40	-79.22
10-17	13G/A	State Street Corp	4.70	-37.24
02-14	13G	T. Rowe Price Investment Management, Inc.	6.90	20.64
02-13	13G/A	Vanguard Group Inc	5.72	-16.82
01-26	13G/A	AltraVue Capital, LLC	4.70	-9.95
01-08	13G/A	BlackRock, Inc.	8.40	-46.75

Top 13F Investors	Shares (1000)	Change (%)	Value ($1000)	Change (%)
(click for more detail)

Date	Insider Trades	Code	Shares	Value
(click for more detail)

File Date	Form	SEC Filings
2024-09-09	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-07-02	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-04-24	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2023 ☐ TRANSITION
2024-04-24	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1)
2024-04-24	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2024 ☐ TRANSITION REPORT PURSUANT T
2024-04-24	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2023 ☐ TRANSITI
2023-12-07	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2023 ☐ TRANSITION REPORT PURSUANT T
(click for more detail)

Short Volume
Market Date	Short Volume	Total Volume	Short Volume Ratio
2024-11-22	212,594	2,095,357	10.15
2024-11-21	87,790	2,179,844	4.03
2024-11-20	126,040	1,030,824	12.23
2024-11-19	202,002	1,552,591	13.01
2024-11-18	137,712	1,168,816	11.78
(click for more detail)

Similar Companies
CARA – Cara Therapeutics, Inc.	CASI – CASI Pharmaceuticals, Inc.
CDIO – Cardio Diagnostics Holdings, Inc.	CDTX – Cidara Therapeutics, Inc.
CDXC – ChromaDex Corporation

Financial data and stock pages provided by
Fintel.io

Related